By: Kairos Ventures On: September 23, 2019 In: Linnaeus, Portfolio News

We are delighted to announce that Linnaeus Therapeutics, Inc. has closed a $12 million series B financing led by...

Read more
By: Kairos Ventures On: September 23, 2019 In: Foldax, Portfolio News

Foldax, Inc. announced its first-in-human use of the Tria heart valve under its FDA Early Feasibility Study (EFS) for...

Read more
By: Kairos Ventures On: August 14, 2019 In: Portfolio News, Tanvas

Kairos Ventures portfolio company, Tanvas, proudly welcomes Phillip LoPresti as Chief Executive Officer. Tanvas, the surface haptic pioneer positions...

Read more
By: Kairos Ventures On: June 17, 2019 In: Portfolio News, Tanvas

Kairos Ventures portfolio company Tanvas joined forces with Mimo Monitors to launch the Mimo Vue with TanvasTouch at InfoComm...

Read more
By: Kairos Ventures On: June 5, 2019 In: MixComm, Portfolio News

Kairos Ventures portfolio company MixComm has appointed Mike Noonen as CEO. The semiconductor veteran joins the leadership team that...

Read more

We are delighted to announce that Actuate Therapeutics is the latest company to join the Kairos portfolio. Founded in...

Read more

We are happy to announce that Xidas is the latest company to join the Kairos portfolio. Xidas is a...

Read more

Rana Gujral has been selected as one of Inc.’s top A.I. entrepreneurs to watch. Rana is CEO of Behavioral...

Read more

Congratulations to Transient Plasma Systems for being selected by the U.S. Department of Energy’s National Renewable Energy Laboratory (NREL) as...

Read more
By: Kairos Ventures On: February 27, 2019 In: Foldax, Portfolio News

Kairos Ventures portfolio company Foldax Inc. announced the U.S. Food and Drug Administration (FDA) has granted investigative device exemption...

Read more